Everpure, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Everpure Inc (NYSE: P) shares rose 3% after CFRA upgraded it from Sell to Buy, citing raised guidance for fiscal 2028. The company projects $7B-$7.3B in revenue and $1.7B-$1.9B in non-GAAP operating income, driven by demand for its all-flash storage solutions in AI data centers. Despite this, GuruFocus's GF Value™ suggests the stock is overvalued at $126.00, with an intrinsic value of $81.40.
Everpure's (NYSE:P) Chief Visionary Officer John Colgrove sold $22.7m in stock, including 200,000 shares at $110.15-$117.54, and gifted 200,000 shares to a trust. Everpure's stock is up 17% in a week, with a market cap of $40.61B. Analysts raised price targets to $150-$162, citing strong fiscal 2028 outlook.
Meta (META) rose 4.5% to $777.59, driven by AI strategy. Everpure (P) surged 11.15% to $121.88, reaffirming fiscal 2027 guidance. Akamai (AKAM) fell 6.78% to $110.41, then jumped 20.65% after-hours on a $11.6B AI deal. Apimeds (APUS) soared 114.85% to $4.92 on a blockchain agreement. Costco (COST) dipped 0.91% to $896.48 despite beating Q4 estimates.
Over the past 7 days, AlphAI's AI scored 14 news stories mentioning P (Everpure, Inc.). Coverage has skewed bullish: 10 bullish, 2 neutral, and 2 bearish.
Recent P coverage spans financial news, earnings and market movers.
In the last 30 days, P insiders filed 16 SEC Form 4 transactions — no purchases and 16 sales ($49.8M). The most active reporter was Colgrove John, Chief Visionary Officer, with 13 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Upgrade and higher guidance support short‑term upside, but valuation remains stretched.
The insider sale may signal confidence concerns and could pressure the stock short‑term.
Guidance raise signals strong growth outlook.
Colgrove John (Chief Visionary Officer) sold 200,000 indirectly-held shares of Everpure, Inc. (P) at an average of $113.26 ($110.15–$117.54, $22.65M total) across 5 trades over 2026-09-22 to 2026-09-24 under a Rule 10b5-1 trading plan.
Strong forward guidance may spark buying interest in the data‑storage niche.
AlphAI scores every news story that mentions P with an AI model for sentiment and relevance, and aggregates insider trades from Everpure, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Everpure Inc (NYSE: P) shares rose 3% after CFRA upgraded it from Sell to Buy, citing raised guidance for fiscal 2028. The company projects $7B-$7.3B in revenue and $1.7B-$1.9B in non-GAAP operating income, driven by demand for its all-flash storage solutions in AI data centers. Despite this, GuruFocus's GF Value™ suggests the stock is overvalued at $126.00, with an intrinsic value of $81.40.
2 min readEverpure's (NYSE:P) Chief Visionary Officer John Colgrove sold $22.7m in stock, including 200,000 shares at $110.15-$117.54, and gifted 200,000 shares to a trust. Everpure's stock is up 17% in a week, with a market cap of $40.61B. Analysts raised price targets to $150-$162, citing strong fiscal 2028 outlook.
2 min readMeta (META) rose 4.5% to $777.59, driven by AI strategy. Everpure (P) surged 11.15% to $121.88, reaffirming fiscal 2027 guidance. Akamai (AKAM) fell 6.78% to $110.41, then jumped 20.65% after-hours on a $11.6B AI deal. Apimeds (APUS) soared 114.85% to $4.92 on a blockchain agreement. Costco (COST) dipped 0.91% to $896.48 despite beating Q4 estimates.
3 min readColgrove John (Chief Visionary Officer) sold 200,000 indirectly-held shares of Everpure, Inc. (P) at an average of $113.26 ($110.15–$117.54, $22.65M total) across 5 trades over 2026-09-22 to 2026-09-24 under a Rule 10b5-1 trading plan.
2 min readUS futures fell, with tech stocks underperforming, as global bond yields hit multi-decade highs and oil prices surged. The 10-year Treasury yield reached 5.14%, and the 30-year yield hit its highest since 2004. Several companies reported premarket moves, including Darden (DRI) down 5% after disappointing sales, and Everpure (P) up 7% on strong revenue forecasts. Investors await a Trump-Xi meeting amid ongoing trade tensions and inflation concerns.
3 min readNeedham raised its price target for Everpure (NYSE:P) to $150 from $140, maintaining a Buy rating. The firm cited Everpure's strong fiscal 2028 outlook, with projected revenue growth of 39% to 45% and operating margins of 24% to 26%. The company also reported second-quarter fiscal 2027 revenue of $1.186 billion, up 38% year-over-year. Several analysts have revised earnings upwards, and the stock has returned 68.3% over the last six months.
2 min readEverpure (NYSE: P) outlined its expansion strategy at its 2026 Financial Analyst Meeting, focusing on four growth vectors: Core and Core AI, Modern Data Software, Scale AI, and Hyperscale Solutions. The company reaffirmed its FY2027 outlook and provided preliminary FY2028 guidance, projecting 20% of total revenue from new growth vectors by FY2030. Everpure has consistently invested 19% of annual revenue in R&D, driving eight consecutive quarters of accelerating revenue growth.
2 min readEverpure Inc (NYSE:P) shares rose 6.9% after-hours after raising its fiscal 2028 revenue outlook to $7.0B-$7.3B (39%-45% YoY growth) and projecting non-GAAP operating income of $1.7B-$1.9B (80%-100% YoY growth). The company also reaffirmed fiscal 2027 guidance and outlined four strategic growth areas.
2 min readEverpure Inc. (NYSE: P) stock rose 6.41% after its inclusion in the S&P 500, replacing The Trade Desk. The company reported $3.66B in revenue, 70.2% gross margin, and a P/E of 392. Analysts expect earnings beats but caution on high valuation and negative free cash flow.
6 min readARK ETFs sold 16,422 Alphabet (GOOGL) shares for $5.8M, bought 359,612 Rocket Lab (RKLB) shares for $25.1M. Also reduced Twist Bioscience (TWST) and 10X Genomics (TXG) positions, while increasing stakes in Scribe Therapeutics (SCTX), Veracyte (VCYT), and Beam Therapeutics (BEAM).
2 min read
